PCSK9 R46L, Lower LDL, and Cardiovascular Disease Risk in Familial Hypercholesterolemia

Association of Low-Frequency and Rare Coding-Sequence Variants with Blood Lipids and Coronary Heart Disease in 56,000 Whites and Blacks

(2014) Gina M. Peloso et al.   AMERICAN JOURNAL OF HUMAN GENETICS

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

(2014) Dirk J. Blom et al.   NEW ENGLAND JOURNAL OF MEDICINE

PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges

(2014) Giuseppe Danilo Norata et al.   VASCULAR PHARMACOLOGY

Regional Distribution and Metabolic Effect of PCSK9 insLEU and R46L Gene Mutations and apoE Genotype

(2013) Zuhier Awan et al.   CANADIAN JOURNAL OF CARDIOLOGY

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

(2013)   LANCET

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

(2013) Kevin Fitzgerald et al.   LANCET

Common and Low-Frequency Genetic Variants in the PCSK9 Locus Influence Circulating PCSK9 Levels

(2012) Ekaterina Chernogubova et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Discriminative Ability of LDL-Cholesterol to Identify Patients With Familial Hypercholesterolemia

(2012) Roeland Huijgen et al.   Circulation-Cardiovascular Genetics

Regulation of Epithelial Sodium Channel Trafficking by Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

(2012) Vikas Sharotri et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The PCSK9 decade

(2012) Gilles Lambert et al.   JOURNAL OF LIPID RESEARCH

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

(2012) Evan A Stein et al.   LANCET

Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population

(2010) Ilaria Guella et al.   JOURNAL OF LIPID RESEARCH

PCSK9R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease

(2010) Marianne Benn et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Differences in characteristics and risk of cardiovascular disease in familial hypercholesterolemia patients with and without tendon xanthomas: A systematic review and meta-analysis

(2009) Daniëlla M. Oosterveer et al.   ATHEROSCLEROSIS

Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes

(2009) Thea Bismo Strøm et al.   CLINICA CHIMICA ACTA

Genetic and Metabolic Determinants of Plasma PCSK9 Levels

(2009) Susan G. Lakoski et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A new method for measurement of total plasma PCSK9: clinical applications

(2009) Geneviève Dubuc et al.   JOURNAL OF LIPID RESEARCH

Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing

(2008) Brian Starr et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Investigations on the evolutionary conservation of PCSK9 reveal a functionally important protrusion

(2008) Jamie Cameron et al.   FEBS Journal

Effect of protein convertase subtilisin/kexin type 9 (PCSK9) 46L gene polymorphism on LDL cholesterol concentration in a Polish adult population

(2008) Grażyna Kostrzewa et al.   MOLECULAR GENETICS AND METABOLISM

APCSK9Missense Variant Associated with a Reduced Risk of Early-Onset Myocardial Infarction

(2008) Sekar Kathiresan   NEW ENGLAND JOURNAL OF MEDICINE